IFPMA, with offices at Campus Biotech, is the body that represents the world leading pharmaceutical and vaccine companies towards the United Nations. Among our member companies are the world’s leading vaccine developers, including Pfizer, Johnson & Johnson, AstraZeneca, Sanofi, GSK and MSD, racing to develop a vaccine for COVID-19.
The event explored the different angles of the new industry business models likely to emerge in a post-pandemic landscape. Our Director General, Tomas Cueni, was joined by executives from large global corporate groups, along with senior experts from global NGOs and multi-lateral organizations, to offer solutions and approaches to current challenges, emerging opportunities, and future threats across multiple industries and sectors.
He was invited to speak in the Healthcare Industry Panel to answer important question such as:
- What has changed most radically in the biopharmaceutical industry during this crisis?
- What is the greatest challenge to overcome in the short term?
- What new business models are likely to emerge?
- And what new opportunities will this create?
During the interview, Thomas Cueni reflected on the unprecedented level of collaboration that we are witnessing during this pandemic and the deep sense of responsibility shared by the biopharmaceutical industry.
You can watch full interview here